Based on our findings in this study, we propose to assess hemolysis parameters (lactate dehydrogenase, haptoglobin, schistocytes) and estimate proteinuria (random urinary protein to creatinine ratio) at the time of occurrence of CMV disease or syndrome, or in case of new onset of thrombocytopenia or a decrease of 25% in blood platelet count in LTx patients. This evidence concerns the gene HP and Down syndrome.